Denali Therapeutics Inc
DNLI13.440USD
0.000
交易中 （美東）報價延遲15分鐘
1.95B總市值
虧損本益比TTM
關於 Denali Therapeutics Inc 公司
Denali Therapeutics Inc. 是一家生物製藥公司。該公司專注於開發一系列候選產品，這些產品經過設計可穿過血腦屏障 (BBB)，用於治療神經退行性疾病和溶酶體貯積症。該公司擁有小分子和生物治療藥物組合，包括七種適應症的七種臨牀開發候選產品以及臨牀前治療候選產品。其三個後期開發項目包括用於治療粘多糖貯積症 II (MPS II) 的 tividenofusp alfa (DNL310)；用於治療帕金森病的 BIIB122/DNL151 (LRRK2 抑制劑)；以及用於治療肌萎縮側索硬化症 (ALS) 的 DNL343 (eIF2B 激活劑)。SAR443820/DNL788 (RIPK1 抑制劑) 正在針對多發性硬化症 (MS) 的 II 期研究中進行評估。此外，該公司還開展了 TAK-594/DNL593 治療額顳葉癡呆-顆粒蛋白 (FTD-GRN) 的 I/II 期研究，以及 DNL126 治療 MPS IIIA (Sanfilippo 綜合徵) 的 I/II 期研究。
公司簡介
公司代碼DNLI
公司名稱Denali Therapeutics Inc
上市日期Dec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
員工數量422
證券類型Ordinary Share
年結日Dec 08
公司地址161 Oyster Point Blvd.
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94080
電話16508668547
網址https://www.denalitherapeutics.com
公司代碼DNLI
上市日期Dec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
768.06K
+20.52%
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
383.89K
+50.87%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
+30.13%
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
768.06K
+20.52%
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
383.89K
+50.87%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月25日 週五
更新時間: 7月25日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Baillie Gifford & Co.
8.32%
The Vanguard Group, Inc.
8.10%
Wellington Management Company, LLP
7.85%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.02%
Other
63.80%
持股股東
持股股東
佔比
Baillie Gifford & Co.
8.32%
The Vanguard Group, Inc.
8.10%
Wellington Management Company, LLP
7.85%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.02%
Other
63.80%
股東類型
持股股東
佔比
Investment Advisor
50.41%
Investment Advisor/Hedge Fund
27.07%
Hedge Fund
10.45%
Individual Investor
4.94%
Corporation
4.93%
Sovereign Wealth Fund
4.42%
Research Firm
2.34%
Pension Fund
0.51%
Bank and Trust
0.30%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
524
153.35M
105.55%
-12.15M
2025Q1
537
151.12M
104.03%
-14.77M
2024Q4
523
145.56M
100.28%
-21.13M
2024Q3
518
152.07M
106.51%
-14.19M
2024Q2
504
147.18M
103.45%
-5.80M
2024Q1
491
145.33M
102.36%
+2.75M
2023Q4
499
138.06M
99.94%
+3.21M
2023Q3
492
132.50M
96.48%
-2.55M
2023Q2
504
131.32M
95.95%
-3.31M
2023Q1
503
131.21M
95.98%
-630.06K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Baillie Gifford & Co.
12.09M
8.32%
-223.89K
-1.82%
Mar 31, 2025
The Vanguard Group, Inc.
11.77M
8.1%
-221.47K
-1.85%
Mar 31, 2025
Wellington Management Company, LLP
11.41M
7.85%
+1.56M
+15.86%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.04M
6.91%
-56.41K
-0.56%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.29M
5.02%
-712.15K
-8.90%
Mar 31, 2025
Biogen Inc
7.16M
4.93%
-5.60M
-43.89%
Oct 30, 2024
Temasek Holdings Pte. Ltd.
5.36M
3.69%
--
--
Mar 31, 2025
UBS Asset Management (Switzerland)
4.88M
3.36%
+1.49M
+43.92%
Mar 31, 2025
Capital Research Global Investors
4.77M
3.28%
-712.07K
-13.00%
Mar 31, 2025
State Street Global Advisors (US)
4.46M
3.07%
-84.22K
-1.85%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
4.17%
Tema Neuroscience and Mental Health ETF
2.07%
ALPS Medical Breakthroughs ETF
1.37%
Global X Guru Index ETF
1.24%
Virtus LifeSci Biotech Clinical Trials ETF
0.84%
BNY Mellon Innovators ETF
0.47%
SPDR S&P Biotech ETF
0.43%
Global X Aging Population ETF
0.33%
iShares Health Innovation Active ETF
0.26%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
查看更多
iShares Neuroscience and Healthcare ETF
佔比4.17%
Tema Neuroscience and Mental Health ETF
佔比2.07%
ALPS Medical Breakthroughs ETF
佔比1.37%
Global X Guru Index ETF
佔比1.24%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.84%
BNY Mellon Innovators ETF
佔比0.47%
SPDR S&P Biotech ETF
佔比0.43%
Global X Aging Population ETF
佔比0.33%
iShares Health Innovation Active ETF
佔比0.26%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.25%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
